Close Menu

NEW YORK – Accelerate Diagnostics reported after the close of the market Thursday that its second quarter revenues were up 17 percent year over year.

The Tucson, Arizona-based maker of test systems for antibiotic resistance and sepsis reported total revenues of $2.1 million versus $1.8 million for the second quarter of 2019, and short of analysts' average expectation for sales of $2.5 million.

The company added six new commercially contracted Pheno instruments in the quarter and brought six live, including four in the US, it said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.